Rhythm Pharmaceuticals is evolving from a single rare disease drug company to a broader therapeutic franchise focused on MC4R treatments. Their drug IMCIVREE has gained approval for AHO and shows strong demand with over 400 patient starts, supported by a scalable commercial model targeting specialists. The company is developing daily, weekly, and oral MC4R agonists to stay ahead of competition and expand market reach. Despite current losses and a premium valuation, accelerating U.S. sales, international expansion, and pipeline progress could justify its high valuation if momentum continues.
Pendle became the second-largest DeFi protocol on OKX's XLayer in less than 30 days, reaching $37.5 million in total value locked (TVL). This rapid growth was driven mainly by a single USDG stablecoin market and integration with Aave V3, which allowe...
Zcash (ZEC) has surged past $1,200, reaching a 30-day gain of 134% and a market cap of $20 billion. Garrett Jin, the largest short seller on Hyperliquid, opened a short position at $444 in July and is now facing an unrealized loss of $25.7 million as...
Ethereum co-founder Vitalik Buterin stated that Bitcoin's security challenges can be addressed through standard software and mining pool updates without needing broad social consensus. He dismissed concerns that AI might cause Bitcoin's price to drop...
Dogecoin surged 4.87% to $0.0902 following a short squeeze in derivatives markets that forced bearish traders to cover positions, driving price momentum. Open interest in DOGE futures spiked 8.5% in one hour to $282 million, pushing the coin above it...
Chainlink (LINK) surged 7.06% in 30 minutes, reaching $13.308 and gaining over 10% in 24 hours with trading volume up 25% to $503 million. Derivatives open interest rose 8.26% to nearly $697 million, signaling increased trader activity. Technical ana...
